arrow_back Back to App

Support for Research in Advanced Pharmaceutical Manufacturing

This act aims to improve support for research and development of new drug manufacturing methods, including continuous production. This could lead to faster and more efficient drug production, potentially resulting in better availability and lower costs for essential health products in the future.
Key points
Increased support for research into innovative drug manufacturing techniques.
Focus on continuous manufacturing of drugs and biological products, potentially speeding up their availability.
Development of new monitoring and quality control techniques in pharmaceutical production.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_3851
Sponsor: Rep. Spanberger, Abigail Davis [D-VA-7]
Process start date: 2021-06-11
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Continuous Manufacturing Research Act of 2021

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_3851.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-06-11.

What are the main provisions?

Key points include:

  • Increased support for research into innovative drug manufacturing techniques.
  • Focus on continuous manufacturing of drugs and biological products, potentially speeding up their availability.
  • Development of new monitoring and quality control techniques in pharmaceutical production.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Spanberger, Abigail Davis [D-VA-7].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on Science, Space, and Technology.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

CATEGORIES

Health Public Investments